DxRxHx
•
•
•
•

Generalized
Anxiety Disorder

An anxiety disorder characterized by excessive, persistent worry about multiple domains of life, accompanied by physical tension and difficulty controlling the worry.

  • 5-6%
    Prevalence
  • ~31
    Onset Age
  • 2:1
    Ratio
  • 50-60%
    Response Rate

DSM-5-TR Diagnostic Criteria

  • Criterion A: Excessive Worry

    Persistent worry for at least 6 months

    • • Excessive anxiety and worry occurring more days than not about a number of events or activities

  • Criterion B: Control

    Difficulty controlling worry

    • • The individual finds it difficult to control the worry

  • Criterion C: Associated Symptoms

    3+ required (only 1 in children):

    • • Restlessness or Feeling Keyed Up (Feeling on edge, unable to relax)
    • • Easily Fatigued (Mental and physical exhaustion from worry)
    • • Difficulty Concentrating (Mind going blank, distracted by worry)
    • • Irritability (Increased impatience and frustration)
    • • Muscle Tension (Chronic tightness, especially jaw, neck, shoulders)
    • • Sleep Disturbance (Difficulty falling/staying asleep, restless sleep)

  • Additional Requirements

    Diagnostic caveats:

    • • Causes clinically significant distress or functional impairment
    • • Not attributable to substance use or medical condition
    • • Not better explained by another mental disorder

Assessment Protocols

Validated tools for screening and severity tracking

  • GAD-7

    Generalized Anxiety Disorder-7

    Brief 7-item self-report measure of GAD symptom severity; one of the most widely used screening tools in primary care.

    Scoring:

    0-4 minimal, 5-9 mild, 10-14 moderate, 15-21 severe anxiety; score ≥10 suggests GAD

    Time:2-3 minutes

  • PSWQ

    Penn State Worry Questionnaire

    Criterion-standard 16-item measure of trait worry, the cardinal feature of GAD.

    Scoring:

    Score range 16-80; cutoff ≥62 suggests clinically significant worry; highly sensitive to treatment change

    Time:5-7 minutes

  • HAM-A

    Hamilton Anxiety Rating Scale

    Clinician-rated 14-item scale assessing psychological and somatic anxiety symptoms.

    Scoring:

    <17 mild, 18-24 mild-moderate, 25-30 moderate-severe, >30 severe anxiety

    Time:15-20 minutes

  • BAI

    Beck Anxiety Inventory

    21-item self-report focusing on somatic symptoms of anxiety over the past week.

    Scoring:

    0-7 minimal, 8-15 mild, 16-25 moderate, 26-63 severe anxiety

    Time:5-10 minutes

Causes & Etiology

  • Neurobiological

    • Amygdala hyperactivity (threat detection)
    • Prefrontal cortex hypoactivity (worry regulation)
    • Anterior cingulate cortex dysfunction
    • GABA and serotonin dysregulation

  • Genetic

    • Heritability: 30-40%
    • Polygenic risk involving multiple genes
    • SLC6A4 polymorphisms
    • COMT gene variants

  • Environmental

    • Childhood adversity and overprotective parenting
    • Chronic stress and major life transitions
    • Socioeconomic instability
    • Medical illness

  • Psychological

    • Intolerance of uncertainty
    • Negative beliefs about worry
    • Thought-action fusion
    • Attentional bias toward threat

Common Comorbidities

  • Major Depressive Disorder

    40-60%

    Frequently co-occurs; either disorder can come first

  • Other Anxiety Disorders

    30-50%

    Panic disorder, social anxiety disorder, and specific phobias commonly co-occur

  • Substance Use Disorders

    15-30%

    Alcohol and benzodiazepine misuse for self-medication; worsens anxiety long-term

  • Somatic Symptom Disorder

    Not well established

    Health worry overlaps with somatic symptom and illness anxiety disorders

  • Irritable Bowel Syndrome

    Elevated

    Anxiety is common in IBS; bidirectional gut-brain links proposed

  • Insomnia Disorder

    40-60%

    Difficulty falling asleep due to worry; sleep disturbance maintains anxiety

Evidence-Based Treatments

  • Cognitive Behavioural Therapy (CBT)

    First-line

    Structured therapy targeting worry content, intolerance of uncertainty, cognitive distortions, and avoidance behaviours.

    Evidence

    Large effect vs control (g 0.84); some evidence gains hold at follow-up

    In practice

    12-16 sessions; includes cognitive restructuring, worry exposure, relaxation training

  • SSRIs/SNRIs

    First-line

    Escitalopram, paroxetine, duloxetine and venlafaxine XR are approved for GAD; sertraline is widely used and recommended by NICE. Increase serotonin/norepinephrine.

    Evidence

    Superior to placebo; 4-8 weeks for full effect

    In practice

    Start low, titrate slowly; continue 12+ months after remission to prevent relapse

  • Acceptance and Commitment Therapy (ACT)

    Alternative

    Mindfulness-based therapy focusing on acceptance of worry rather than control; values-based action.

    Evidence

    Promising in trials; smaller evidence base than CBT

    In practice

    Targets experiential avoidance and cognitive fusion with anxious thoughts

  • Buspirone

    Adjunct

    5-HT1A partial agonist; anxiolytic without sedation or dependence risk.

    Evidence

    Modest effect; no immediate relief (2-4 weeks onset)

    In practice

    Option for clients with a substance use history; sometimes used to augment SSRIs

  • Pregabalin

    Adjunct

    Anticonvulsant with anxiolytic properties; modulates calcium channels.

    Evidence

    Approved for GAD in Europe (not in Canada or the US); faster onset than SSRIs

    In practice

    Monitor sedation, dizziness and weight gain; misuse and dependence are reported

  • Mindfulness-Based Stress Reduction (MBSR)

    Adjunct

    8-week structured program teaching mindfulness meditation and body awareness.

    Evidence

    Moderate effect sizes; reduces worry and physiological arousal

    In practice

    Can be combined with CBT or medication; requires practice commitment

Try it with one client

Send a PHQ-9 or GAD-7 by secure link and read the scored result before the session.

Start

Generalized Anxiety Disorder questions

  • What is Generalized Anxiety Disorder?

    Generalized Anxiety Disorder (GAD) is an anxiety disorder defined in DSM-5-TR (ICD-10 code F41.1) by excessive, persistent worry about multiple domains of life lasting at least 6 months, accompanied by physical tension and difficulty controlling the worry. The worry is hard to control and produces clinically significant distress or functional impairment. Three or more associated symptoms are required for adults: restlessness, fatigue, difficulty concentrating, irritability, muscle tension, or sleep disturbance.

  • What are the symptoms of Generalized Anxiety Disorder?

    Core symptoms include excessive worry about multiple life domains (work, health, family, finances), difficulty controlling the worry, and physical and cognitive symptoms that accompany the anxiety. Associated symptoms include restlessness or feeling on edge, easy fatigue, difficulty concentrating or mind going blank, irritability, muscle tension (especially jaw, neck, and shoulders), and sleep disturbance. Symptoms must be present more days than not for at least 6 months and cause functional impairment to meet diagnostic threshold.

  • How is Generalized Anxiety Disorder diagnosed?

    Diagnosis is made by a clinician using DSM-5-TR criteria, supported by validated scales. The GAD-7 (7 items, 2 to 3 minutes) is one of the most widely used screeners; a score of 10 or above suggests probable GAD with 89% sensitivity and 82% specificity. The PSWQ (Penn State Worry Questionnaire) measures trait worry. The HAM-A is a clinician-rated alternative for severity. A full clinical evaluation rules out medical conditions (hyperthyroidism, cardiac issues), substance-induced anxiety, and other anxiety or mood disorders that might better explain the presentation.

  • What causes Generalized Anxiety Disorder?

    GAD has moderate genetic heritability of 30 to 40 percent, with polygenic risk spread across many genes of small effect. Neurobiologically, GAD involves amygdala hyperactivity for threat detection, prefrontal cortex hypoactivity for worry regulation, anterior cingulate cortex dysfunction, and GABA and serotonin dysregulation. Environmental contributors include childhood adversity, overprotective parenting, chronic stress, major life transitions, and socioeconomic instability. Psychological maintaining factors include intolerance of uncertainty, negative beliefs about worry, and attentional bias toward threat.

Scientific Sources

Evidence-Based

  • GAD-7 Validation

    Spitzer RL, Kroenke K, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.

  • DSM-5-TR Criteria

    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.

  • CBT for GAD Meta-Analysis

    Cuijpers P, Cristea IA, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis. World Psychiatry. 2016;15(3):245-258.

  • Pharmacotherapy Efficacy

    Baldwin DS, Anderson IM, et al. Evidence-based pharmacological treatment of anxiety disorders. J Psychopharmacol. 2014;28(5):403-439.

  • Intolerance of Uncertainty Model

    Dugas MJ, Gagnon F, et al. Generalized anxiety disorder: a preliminary test of a conceptual model. Behav Res Ther. 1998;36(2):215-226.

  • Neurobiology of GAD

    Etkin A, Prater KE, et al. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009;66(12):1361-1372.